



Prescription Stimulants and the Development of Post-Traumatic Stress Disorder Among U.S. Service Members

*Nancy F. Crum-Cianflone
Melissa A. Frasco
Cynthia LeardMann
Christopher Phillips
Jaime Horton
Dale W. Russell
Margaret A. K. Ryan*



Naval Health Research Center

*Report No. 13-47 supported by Bureau of Medicine and Surgery
under Work Unit No. 60002.*

*The views expressed in this article are those of the authors and do not
necessarily reflect the official policy or position of the Department of the
Navy, Department of Defense, nor the U.S. Government.
Approved for public release; distribution unlimited.*

*This research was conducted in compliance with all applicable federal
regulations governing the protection of human subjects in research.*

*Naval Health Research Center
140 Sylvester Road
San Diego, California 92106-3521*

Prescription Stimulants and the Development of Post-Traumatic Stress Disorder Among U.S. Service Members

Nancy F. Crum-Cianflone, M.D., M.P.H.,^{1,2}

Melissa A. Frasco, Ph.D.¹

Cynthia LeardMann, M.P.H.¹

Christopher Phillips, M.D., M.P.H.¹

Jaime Horton, M.P.H.¹

Dale W. Russell, Ph.D.³

Margaret A. K. Ryan, M.D., M.P.H.⁴

¹ Deployment Health Research Department,
Naval Health Research Center, San Diego, California

² Naval Medical Center, San Diego

³ Center for the Study of Traumatic Stress, Uniformed Services University
of the Health Sciences, Bethesda, Maryland

⁴ Naval Hospital, Camp Pendleton, California

Report 13-47, supported by the Department of Defense, under Work Unit No. 60002. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of the Army, Department of the Air Force, Department of Defense, Department of Veterans Affairs, or the U.S. Government. Approved for public release; distribution is unlimited. This research was conducted in compliance with all applicable federal regulations governing the protection of human subjects (Protocol NHRC.2000.0007).

ABSTRACT

Background

Post-traumatic stress disorder (PTSD) occurs among both civilians and military personnel after traumatic events, and has become a signature wound of the recent conflicts in Iraq and Afghanistan. The relationship between novel risk factors, such as prescription stimulants, and the subsequent development of PTSD is unknown.

Methods

We studied 25910 military members from a large prospective cohort that began enrollment prior to September 11th, 2001. Medication prescriptions were obtained from the military Pharmacy Data Transaction Service, and PTSD was based on a validated survey instrument (PTSD Checklist–Civilian Version) during the study period (2001–2008). The risk of incident PTSD with stimulant use was estimated using survival analyses, while adjusting for sociodemographic factors, military service characteristics, baseline mental and physical health status, deployment experiences (e.g., combat), and physical/sexual trauma.

Results

Overall, 1368 (5.3%) persons developed incident PTSD during follow-up. Prescription stimulants were significantly associated with incident PTSD (hazard ratio [HR], 3.66; 95% confidence interval [CI], 2.48–5.41; $p < 0.001$) in the adjusted model. The magnitude of this association exceeded that of a combat deployment and incident PTSD (HR, 1.61; 95% CI, 1.41–1.83; $p < 0.001$). A dose-related relationship between the days' supply and number of stimulant prescriptions with PTSD was noted (p trend < 0.001).

Conclusions

The findings suggest that prescription stimulants may increase the risk of subsequent development of PTSD. These data may inform the underlying pathogenesis of and preventive strategies for PTSD.

Post-traumatic stress disorder (PTSD) has been increasingly reported among U.S. service members in association with the recent conflicts in Iraq and Afghanistan, with an estimated post-deployment prevalence of 5.5% in population samples and 13.2% in operational infantry units.¹ With over 2.5 million service members having deployed at least once to the recent conflicts, the number of PTSD cases and their associated costs are substantial.^{2,3} Further, PTSD represents an important health condition in the general population, with a reported lifetime prevalence of 4–10%.⁴

Traumatic experiences predate the onset of PTSD. Among military personnel, the most potent risk factor identified to date has been combat experiences, such as handling dead bodies, knowing someone who was killed, or killing enemy combatants.^{5,6} Although several other pre-, during, and post-event risk factors have been identified,⁷ the development of PTSD is not completely explained by these factors.

A recent report suggested a potential link between the increasing use of stimulants and the rising incidence of PTSD⁸; however, scientific research data are lacking. In both military and civilian settings, prescription stimulants may be used for conditions such as attention deficit disorder (ADD)/attention deficit hyperactivity disorder (ADHD) or to enhance performance, and such use has increased in recent decades.^{9,10} In select military groups, stimulants may also be prescribed to reduce fatigue and improve cognitive abilities during periods of sleep deprivation.¹¹⁻¹³

Pathophysiological relationships may exist between stimulant medications and the development of PTSD. Exposure to a traumatic event leads to an increase in adrenergic (e.g., norepinephrine) levels and activation of the amygdala, creating memories of the event.^{14,15} Increased norepinephrine levels prior to, or shortly after, a traumatic event have been shown to result in more vivid, long-lasting memories.^{16,17} Hence, the use of stimulants, which are known

to increase norepinephrine levels in the brain, could result in an increased incidence of PTSD following traumatic exposures. Unlike adrenergic mediators, centrally acting beta blockers, which inhibit norepinephrine, had a protective effect in some, but not all, studies.¹⁸⁻²⁰

Although PTSD is one of the most important mental health conditions and a signature wound of the post-2001 Iraq and Afghanistan conflicts, to our knowledge there is no prospective research on the relationship between prescription stimulants and the subsequent development of PTSD. We utilized the Millennium Cohort Study, the largest prospective epidemiologic study in U.S. military history, to examine the association between prescription stimulants and subsequent PTSD, while controlling for multiple covariates including deployment experiences and prior sexual/physical trauma. This study was undertaken to potentially identify a novel risk factor for the development of PTSD, and to inform existing policies on the use of stimulants.

METHODS

Study Population

The Millennium Cohort Study began in 2001, just prior to the start of the conflicts in Iraq and Afghanistan. The study was approved by the Naval Health Research Center institutional review board, and all participants provided voluntary informed consent. Invited participants (n=256,400) to the first panel were randomly selected from U.S. military personnel serving in October 2000, with an oversampling of women, Reserve and National Guard, and members previously deployed to Bosnia, Kosovo, or Southwest Asia. Participants completed a comprehensive baseline survey as well as follow-up surveys approximately every 3 years thereafter. A detailed description of study methodology has been previously reported.²¹ The first enrollment panel consisted of 77,047 participants (2001–2003), of whom 55,021 (71%)

completed the first follow-up questionnaire (2004–2006) and 54,790 (71%) completed the second follow-up questionnaire (2007–2008).

The study population for this analysis included participants who were active-duty members at baseline survey completion, completed at least the first follow-up survey, and had data within the military electronic medical record (EMR) system (n=28,952). Further exclusions included missing baseline covariate data (n=1480), missing combat experience from follow-up surveys (n=14), single stimulant prescriptions of <30 days' supply (n=31) since the accuracy in these limited pharmacy transactions could not be verified, and receipt of a non-stimulant ADD/ADHD medication (atomoxetine, n=61). To evaluate incident PTSD, those who had a positive PTSD screen or reported a prior diagnosis on the baseline survey (n=1456) were excluded (study population, n=25,910). To evaluate the relationship between stimulants and PTSD, independent of underlying ADD/ADHD diagnosis, analyses were repeated excluding participants with ADD/ADHD (study population, n=25,658).

Outcome

Due to the complexity of diagnosing PTSD and the underdiagnosis of this condition in military personnel, PTSD was assessed using the PTSD Checklist–Civilian Version. This 17-item measure of PTSD symptoms was interpreted according to *Diagnostic and Statistical Manual of Mental Disorders, 4th Edition*, criteria.^{22,23} This instrument has been validated, used extensively in military populations, and has demonstrated good internal consistency in this cohort.^{22,24,25} Incident PTSD was defined as meeting the criteria at follow-up among those who both screened negative for PTSD and did not report a history of health professional-diagnosed PTSD at baseline.

In a subanalysis, EMR data were evaluated (including visits to military medical treatment facilities [MTFs] and other reimbursable facilities [e.g., TRICARE, a Department of Defense

(DoD) program that provides health care coverage for medical services and medications]) for the diagnosis of PTSD using *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM) code 309.81.²⁶ The study population for this analysis consisted of active-duty members with complete survey data and excluded those with an ICD-9 diagnosis for PTSD prior to baseline survey (study population, n=27,835).

Exposure of Interest

Prescription stimulant data were obtained using the Pharmacy Data Transaction Service (PDTs), which records each prescription event within MTFs and TRICARE. Data included the medication name, date of dispensing event, number of days' supply, and number of refills. For this study, prescription stimulants were defined as a prescription for methylphenidate, dextroamphetamine, amphetamine, modafinil, armodafinil, methamphetamine, lisdexamfetamine, pemoline, dexmethylphenidate, and/or phentermine.

Covariates

Demographic and military-specific data, obtained from electronic military personnel files maintained by the Defense Manpower Data Center (DMDC), included sex, race/ethnicity, year of birth, highest education level, marital status, pay grade, military service branch and component, and duty occupation. Based on Millennium Cohort data on combat-like experiences (personal exposure to least one of the following: witnessing death, physical abuse, dead and/or decomposing bodies, maimed soldiers or civilians, or prisoners of war or refugees) and DMDC data on in- and out-of-theater dates, participants were categorized as nondeployed, deployed without combat-like experiences, or deployed with combat-like experiences. In addition, alcohol-related problems (using the Patient Health Questionnaire),²⁷ tobacco use, self-reported prior physical assault or sexual trauma, and physical component summary (PCS) and mental component summary (MCS) scores (from the Medical Outcomes Study Short Form 36-Item

Health Survey for Veterans) were included.²⁸ All covariates were assessed at baseline, while deployment and combat experiences were examined as time-varying covariates in the models.

Statistical Analysis

Characteristics of participants who did and did not receive a prescription stimulant medication were compared utilizing chi-square statistics and t-tests. Since incident PTSD symptoms were reported at the time the first or second follow-up survey was administered, rather than at the precise initiation of symptoms, discrete-time survival analysis²⁹ was used to investigate the association of stimulant medication prescription on incident PTSD. These analyses assumed an underlying continuous-time proportional hazards model, and a complementary log-log model using logistic regression was fitted. Person-years at risk were calculated from study entry (baseline survey completion) until development of the outcome (PTSD) or last completed survey. Estimates of the relationships between the exposure and the outcome were calculated as estimated hazard ratios (HRs) with 95% confidence intervals (CIs). The analysis was repeated excluding all participants with a diagnosis of ADD/ADHD (ICD-9 318.0–318.01).

In a subanalysis, PTSD diagnosis by an EMR ICD-9 code was examined using continuous-time survival analysis with Cox proportional hazards. Person-years at risk were calculated from the time of study entry until the earliest date of the occurrence of a PTSD code, military separation, death, or end of follow-up for this study (6 months after final survey completion). Data management and statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Inc., Cary, North Carolina).

RESULTS

The study population consisted of 25,910 active-duty members, of whom 257 (1.0%) received a stimulant prescription during follow-up (mean, 5.0 years; standard deviation, 1.2). The most common type of stimulant initially prescribed was modafinil (n=99, 39%), followed by methylphenidate (n=83, 32%), dextroamphetamine (n=41, 16%), and other stimulants (n=34, 13%). Characteristics of military personnel who received a stimulant prescription are shown in Table 1.

Overall, 1368 (5.3%) persons developed incident PTSD during follow-up. Of those, 2% had received a prescription stimulant prior to PTSD symptom reporting. In the unadjusted analysis, receipt of a prescription stimulant was associated with incident PTSD (HR, 3.39; 95% CI, 2.10–5.46). In the final adjusted model, stimulants remained significantly associated with PTSD (Table 2; HR, 3.66; 95% CI, 2.48–5.41). Other factors associated with incident PTSD included combat deployment, female sex, non-white race/ethnicity, non-Air Force branch, enlisted pay grade, alcohol-related problems, being a current or past smoker, prior physical assault/sexual trauma, and lower baseline MCS and PCS scores (Table 2).

There was a dose relationship between the days' supply of a prescription stimulant and incident PTSD symptoms in adjusted models: 30–89 days versus 0 days (HR, 2.83; 95% CI, 1.45–5.48) and ≥ 90 days versus 0 days (HR, 4.29; 95% CI, 2.64–6.96). Similarly, the number of stimulant prescriptions was also associated with incident PTSD: 1–3 versus 0 prescriptions (HR, 2.91; 95% CI, 1.60–5.29) and ≥ 4 versus 0 prescriptions (HR, 4.46; 95% CI, 2.67–7.46). There was a significant trend for increasing risk of PTSD with increasing days supply and number of prescriptions (Table 3A, p trend < 0.001).

In the adjusted model excluding participants with ADD/ADHD, the risk of incident PTSD was magnified in stimulant users (HR, 3.79; 95% CI, 2.33–6.15). A significant

relationship between cumulative days' supply and number of stimulant prescriptions with incident PTSD was also observed (Table 3B, p trend <0.001).

In the subanalysis, 441 (1.6%) had an ICD-9 code for PTSD. Among the 231 active-duty service members who received a prior stimulant prescription in this analysis, 6 (2.6%) were subsequently diagnosed with PTSD. The findings were in the same direction as the primary model (adjusted HR for stimulant use and incident PTSD: 1.48 [95% CI, 0.66–3.33]), although not statistically significant.

DISCUSSION

This study is the first rigorous scientific investigation regarding the association between prescription stimulant medications and incident PTSD among U.S. military personnel during the post-2001 Iraq and Afghanistan conflicts. The findings show a strong and significant association between the receipt of a stimulant prescription and the development of incident PTSD, with the magnitude of association greater than described for combat deployment experiences and subsequent PTSD.

The rise in the number of PTSD cases during the past decade among military troops has been attributed to intense combat and other occupational exposures. Studies have consistently noted that combat experiences, such as killing enemy combatants and greater perceived threat, are related to post-deployment PTSD.^{5,6} Whether an increasing use of stimulants during this past decade^{9,10} is also related to the rising incidence of PTSD in the military has been hypothesized but previously unstudied.⁸ Prior studies in the general population have largely been confined to evaluating PTSD as a risk factor for subsequent illicit drug use.³⁰⁻³² This study is the first to provide prospective evidence that prescription stimulants are associated with a higher risk of subsequent PTSD. While most cases of incident PTSD in our cohort were not prescribed

stimulants, our findings suggest that stimulants may be contributing to some of the PTSD cases among military personnel.

Stimulant medications (specifically dextroamphetamine and modafinil) have been used off label to heighten cognitive performance and reduce fatigue among select military troops, especially during operations that entail sleep deprivation (e.g., long flight missions).^{11,12} The use of stimulant medications among military troops for these purposes dates back to World War II, and stimulants were utilized in Vietnam (at reportedly higher doses) and missions to Libya, the Falklands, and Operations Desert Shield and Desert Storm.¹¹ In the current era, stimulant prescriptions for fatigue reduction and/or performance enhancement is guided by specific military policies and only authorized for select aviation professionals,¹² with studies showing use during 57–96% of missions depending on the flight duration.¹³ Use among other military personnel may also be occurring given a recent DoD survey finding stimulant misuse among 2–3% of personnel.³³

Although no major problems have been reportedly attributed to stimulants in the military,¹² most studies were conducted in controlled settings and in-theater data are sparse. Further, no prior studies have specifically examined incident PTSD after stimulant use. Short-term side effects of stimulants include tachycardia, increased blood pressure, and jitteriness, likely the result of increased norepinephrine levels. Since increased noradrenergic (e.g., norepinephrine) levels at the time of a traumatic event create more vivid, long-lasting memories and fear of the event,^{14,15} stimulants could potentially increase the incidence of PTSD following traumatic exposures.

The effect of stimulants on PTSD may vary both by the occurrence of subsequent traumatic exposures and by individual genetic characteristics. Among amphetamine users, those with specific single nucleotide polymorphisms in dopaminergic system genes have a heightened

risk for PTSD.³⁴ Further, specific polymorphisms (e.g., catechol-0-methyltransferase genes) have been associated with an individual's responsivity to stimulants during sleep loss.³⁵ Further research on potential gene–environmental interactions among service members who develop PTSD, especially in cases where stimulants were utilized, are needed.

Since stimulants are used to treat ADD/ADHD, and ADD/ADHD may increase the risk for PTSD^{36,37} and these conditions may share a common pathophysiology,^{38,39} analyses were repeated excluding service members with diagnosed ADD/ADHD. The strong relationship between stimulant prescriptions and PTSD persisted, suggesting that this relationship is independent of ADD/ADHD. While it is possible that ADD/ADHD diagnoses were not recorded, this is unlikely since we excluded anyone with a single ADD/ADHD ICD-9 code occurring anytime during the study period, and prescriptions for controlled medications are typically linked with specific medical codes.

This study highlights the potential risks of using stimulants in operational settings. Although the overall number of PTSD cases linked to stimulant use was small, the potential costs from this novel risk factor may be substantial. For example, if 5% of the ~2.5 million personnel deployed to Operations Iraqi Freedom and Enduring Freedom developed incident PTSD¹ and stimulants contributed to 2% of these cases, the cost would be nearly \$26 million during a 2-year period, with an estimated lifetime cost of \$3.8 billion.^{2,3} Extending these findings to the general population would result in substantial health-related costs. In addition to the financial costs of PTSD, there are also important effects on quality of life and associated comorbidities among individuals with PTSD and their families. Given these potential health risks, the use of stimulants in settings where the risk of PTSD is elevated should be further studied and deliberated.

Limitations of this work include the small number of military members prescribed stimulants, the lack of data on actual use of the prescribed medication, and that the number of

PTSD cases attributable to stimulants may have been underestimated if medications were not recorded in the PDTS (e.g., obtained from non-military/TRICARE sources or missing from in-theater records). It is unlikely that any potential missed prescriptions accounted for our study's findings, since this would have likely resulted in a non-differential effect and a reduced magnitude of the association. PTSD symptoms were reported on the survey, thus we were not definitively able to ascertain the exact timing of symptom onset in relation to medication use; however, stimulants are rarely used to treat PTSD and are not part of the DoD/Department of Veterans Affairs PTSD management guidelines.⁴⁰ Further, additional analyses examined the date of ICD-9 diagnosis to confirm that PTSD occurred after the first prescription of the stimulant with findings in the same direction, albeit not significant possibly due to the small sample size. The primary model was based on PTSD by validated survey instruments as the majority of PTSD cases in the military are often not represented in the medical records due to stigma and the use of alternate codes. The Millennium Cohort represents a population-based sample of military members, and although potential biases may exist, previous studies have shown that participants self-report data reliably, well represent the U.S. military, and were not influenced to participate based on prior health.²¹ Finally, in addition to stimulants, sedatives may be used to enhance sleep after missions ("go pills" and "no-go pills," respectively); we did not evaluate the use of sedatives, but it is possible that stimulants were used to counter the effects of sleep inducers, and vice versa, which should be investigated in future research.

This study provides critical information regarding the identification of a potential novel risk factor for the development of PTSD. These data may inform the underlying pathogenesis of and preventive strategies for PTSD, as well as inform future policies regarding the use of prescription stimulants in specific occupational settings.

ACKNOWLEDGMENTS

In addition to the authors, the Millennium Cohort Study Team includes Lauren Bauer, M.P.H.; Evelyn Davila, Ph.D.; Raechel Del Rosario, M.P.H.; CPT Carrie Donoho, Ph.D.; Melissa Frasco, Ph.D.; Andrea Ippolito; Isabel Jacobson, M.P.H.; Cynthia LeardMann, M.P.H.; William Lee; Hector Lemus, Dr.PH., M.S.; Michelle Linfesty; Denise Lovec-Jenkins; Gordon Lynch; Jill MacDougal; Shelia Medina-Torne, M.P.H.; Anna Nagel, M.P.H.; Roy Nesbitt, M.A.; Christopher Phillips, M.D., M.P.H.; Roy Nesbitt, M.A.; Toni Rush, M.P.H.; Kari Sausedo, M.A.; Emma Schaller, M.P.H.; Carter Seveck, M.S.; Beverly Sheppard; Donald Slymen, Ph.D.; Katherine Snell; Steven Speigle; Daniel Trone, Ph.D.; Kartavya Vyas; Jennifer Walstrom; John Wesner, M.P.H.; Martin White, M.P.H.; and James Whitmer.

References

1. Kok BC, Herrell RK, Thomas JL, Hoge CW. Posttraumatic stress disorder associated with combat service in Iraq or Afghanistan: reconciling prevalence difference between studies. J Nerv Ment Dis 2012, 200, 444-50.
2. Tanielian T, Jaycox L (eds). Invisible wounds of war: psychological and cognitive injuries, their consequences, and service to assist recovery. RAND Corporation, 2008.
(<http://www.rand.org/pubs/monographs/MG720.html>).
3. Kime P. DoD orders review of mental health diagnoses. Springfield, VA: ArmyTimes; 2009. (Accessed January 30, 2013 at <http://www.armytimes.com/article/20120613/NEWS/206130303/DoD-orders-review-mental-health-diagnoses>).
4. Kessler RC, Berglund P, Delmer O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62, 593-602.
5. Hoge CW, Castro CA, Messer SC, et al. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 2004, 351, 13-22.
6. Phillips CJ, LeardMann CA, Gumbs GR, Smith B. Risk factors for posttraumatic stress disorder among deployed U.S. male marines. BMC Psychiatry 2010, 10, 52.
7. Hermann BA, Shiner B, Friedman MJ. Epidemiology and prevention of combat-related post-traumatic stress in OEF/OIF/OND service members. Mil Med 2012; 177(Suppl 8), 1-6.
8. Friedman R. Why are we drugging our soldiers? New York Times, April 22, 2012.
9. Fortuna RJ, Robbins BW, Caiola E, Joynt M, Halterman JS. Prescribing of controlled medications to adolescents and young adults in the United States. Pediatrics 2010, 126(6), 1108-1116.

10. Lakhan SE, Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain Behav 2012, 2(5), 661-77.
11. Davenport N, Lowry C, Pinkston B. Use of stimulants in operational settings: issues and considerations. In: Wesensten NJ, ed. Sleep deprivation, stimulant medications, and cognition. Cambridge: Cambridge University Press, 2012, 237-56.
12. Caldwell JA, Mallis MM, Caldwell JL, Paul MA, Miller JC, Neri DF. Aerospace Medical Association Fatigue Countermeasures Subcommittee of the Aerospace Human Factors Committee. Fatigue countermeasures in aviation. Aviat Space Environ Med 2009, 80, 29-59.
13. Gore RK, Webb TS, Hermes ED. Fatigue and stimulant use in military fighter aircrew during combat operations. Aviat Space Environ Med 2010; 81, 719-27.
14. Debiec J, Bush DEA, LeDoux JE. Noradrenergic enhancement of reconsolidation in the amygdala impairs extinction of conditioned fear in rats—a possible mechanism for the persistence of traumatic memories in PTSD. Depress Anxiety 2011; 28, 186-93.
15. Shin LM, Rauch SL, Pitman RK. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci 2006; 1071, 67-79.
16. Southwick SM, Davis M, Horner B, et al. Relationship of enhanced norepinephrine activity during memory consolidation to enhanced long-term memory in humans. Am J Psychiatry 2002; 159, 1420-2.
17. Soeter M, Kindt M. Noradrenergic enhancement of associative fear memory in humans. Neurobiol Learn Mem 2011; 96, 263-71.
18. Reist C, Duffy JG, Fujimoto K, Cahill L. Beta-adrenergic blockade and emotional memory in PTSD. Int J Neuropsychopharmacol 2001; 4, 377-83.

19. Soeter M, Kindt M. Erasing fear for an imagined threat event. Psychoneuroendocrinology 2012; 37, 1769-79.
20. O'Carroll RE, Drysdale E, Cahill L, Shajahan P, Ebmeier KP. Memory for emotional material: a comparison of central versus peripheral beta blockade. J Psychopharmacol 1999; 13, 32-9.
21. Crum-Cianflone NF. The Millennium Cohort Study: answering long-term health concerns of US military service members by integrating longitudinal survey data with Military Health System records. In: Amara J, Hendricks A, eds. Military medical care: from predeployment to post- separation, Abingdon: Routledge, 2013: p 55-77.
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 2000.
23. Brewin CR. Systematic review of screening instruments for adults at risk of PTSD. J Trauma Stress, 2005; 18, 53-62.
24. Terhakopian A, Sinaii N, Engel CC, Schnurr PP, Hoge CW. Estimating population prevalence of posttraumatic stress disorder: an example using the PTSD Checklist. J Trauma Stress, 2008; 21, 290-300.
25. Smith TC, Smith B, Jacobson IG, Corbeil TE, Ryan MA; for the Millennium Cohort Study Team. Reliability of standard health assessment instruments in a large, population-based cohort study. Ann Epidemiol, 2007;17:271-84.
26. Mental disorders and mental health problems, active component, U.S. Armed Forces, 2000–2011. Medical Surveillance Monthly Report. Silver Spring, MD: Armed Forces Health Surveillance Center, 2012; 19(6), 11-17.
27. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. JAMA, 1999; 282, 1737-44.

28. Kazis LE, Lee A, Spiro A III, et al. Measurement comparisons of the Medical Outcomes Study and veterans SF-36 Health Survey. Health Care Financ Rev, 2004; 25(4), 43-58.
29. Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press, 2003.
30. Smith RC, Blumenthal H, Badour C, Feldner MT. An investigation of relations between crystal methamphetamine use and posttraumatic stress disorder. Addict Behav, 2010; 35, 625-7.
31. Tull MT, Gratz KL, Aklin WM, Lejuez CW. A preliminary examination of the relationships between posttraumatic stress symptoms and crack/cocaine, heroin, and alcohol dependence. J Anxiety Disord 2010. doi: 10.1016/j.janxdis.2009.08.006.
32. Chilcoat HD, Breslau N. Posttraumatic stress disorder and drug disorders: testing causal pathways. Arch Gen Psychiatry, 1998; 55, 913-7.
33. Jeffery DD, Babeu LA, Nelson LE, Kloc M, Klette K. Prescription drug misuse among U.S. active duty military personnel: a secondary analysis of the 2008 DoD survey of health related behaviors. Mil Med. 2013;178(2):180-95.
34. Nelson EC, Heath AC, Lynskey MT, et al. PTSD risk associated with a functional DRD2 polymorphism in heroin-dependent cases and controls is limited to amphetamine-dependent individuals. Addict Biol 2013. doi: 10.1111/adb.12062.
35. Quartana PJ, Rupp TL. Genetic basis of individual vulnerability to sleep loss and responsitivity to stimulants. In: Wesensten NJ, ed., Sleep deprivation, stimulant medications, and cognition. Cambridge: Cambridge University Press, 2012; 43-57.
36. Antshel KM, Kaul P, Biederman J, et al., Posttraumatic stress disorder in adult attention-deficit/hyperactivity disorder: clinical features and familial transmission. J Clin Psychiatry, 2013; 74, e197-204

37. Biederman J, Petty C, Spencer TJ, et al. Is ADHD a risk for posttraumatic stress disorder (PTSD)? Results from a large longitudinal study of referred children with and without ADHD. World J Biol Psychiatry, 2013 April 23. [Epub ahead of print].
38. Adler LA, Kunz M, Chua HC, Rotrosen J, Resnick SG. Attention-deficit/hyperactivity disorder in adult patients with posttraumatic stress disorder (PTSD): is ADHD a vulnerability factor? J Atten Disord, 2004; 8, 11-6.
39. Harrington KM, Miller MW, Wolf EJ, Reardon AF, Ryabchenko KA, Ofrat S. Attention-deficit/hyperactivity disorder comorbidity in a sample of veterans with posttraumatic stress disorder. Compr Psychiatry, 2012; 53, 679-90.
40. VA/DoD clinical practice guideline for management of post-traumatic stress, 2010. (Accessed June 17, 2013 at http://www.healthquality.va.gov/ptsd/cpg_PTSD-FULL-201011612.pdf).

Table 1. Stimulant Prescriptions among Military Members (N = 25,910).

Baseline Characteristics [*]	No Stimulant Rx N = 25,653		Stimulant Rx [†] N = 257	
	n	%	n	%
Deployment experience [‡]				
Non-deployed	13,623	53.1	129	50.2
Deployed with combat	5412	21.1	57	22.2
Deployed without combat	6618	25.8	71	27.6
Sex				
Male	19,828	77.3	192	74.7
Female	5825	22.7	65	25.3
Birth cohort				
Pre-1960	3224	12.6	37	14.4
1960–1969	11,445	44.6	124	48.2
1970–1979	9910	38.6	91	35.4
1980 and beyond	1074	4.2	5	2.0
Race/ethnicity				
Non-Hispanic white	16,447	64.1	193	75.1
Non-Hispanic black	3318	12.9	20	7.8
Other	5888	23.0	44	17.1
Highest level of education				
Some college or less	17,677	68.9	142	55.3
Bachelor's or higher	7976	31.1	115	44.7
Marital status				
Never married	6711	26.1	46	17.9
Currently married	17,690	69.0	198	77.0
Separated, divorced, or widowed	1252	4.9	13	5.1
Service branch				
Army	10,205	39.8	86	33.5
Navy/Coast Guard	5919	23.1	45	15.5
Marine Corps	1391	5.4	6	2.3
Air Force	8138	31.7	120	46.7
Military pay grade				
Enlisted	18,049	70.4	152	59.1
Officer	7604	29.6	105	40.9
Occupation				
Combat specialist	5881	22.9	71	27.6
Health care	2650	10.3	39	15.2
Other	17,122	66.7	147	57.2
Alcohol-related problems [§]				
No	23,399	91.2	240	93.4
Yes	2254	8.8	17	6.6
Cigarette smoking				
Non-smoker	15,534	60.6	161	62.7
Past smoker	6029	23.5	63	24.5
Current smoker	4090	15.9	33	12.8

Prior physical assault/sexual trauma [¶]				
No	22,203	86.5	215	83.7
Yes	3450	13.4	42	16.3
Mental component summary score ^{**}				
<15th percentile	2822	11.0	40	15.6
15th–85th percentile	18,827	73.4	189	73.5
>85th percentile	4004	15.6	28	10.9
Physical component summary score ^{**}				
<15th percentile	3500	13.6	45	17.5
15th–85th percentile	18,595	72.5	172	66.9
>85th percentile	3558	13.9	40	15.6

* Characteristics were evaluated at the baseline survey, except for deployment

experience. Using chi-square statistics to compare service members who received a stimulant prescription compared to those who did not, all characteristics were statistically significant different ($P < 0.05$) in the univariate analyses except for deployment experience, sex, birth year category, alcohol-related problems, smoking status, prior physical assault/sexual trauma, and physical component score (PCS).

[†] Obtained from pharmacy records, any prescription(s) for the following stimulants from 2002 to the date of the last follow-up survey were included: methylphenidate, dextroamphetamine, amphetamine, modafinil, armodafinil, methamphetamine, lisdexamfetamine, pemoline, dexmethylphenidate, and/or phentermine.

[‡] Deployment in support of the operations in Iraq and Afghanistan between baseline and the last completed follow-up.

[§] Assessed using five alcohol use questions from the Patient Health Questionnaire.

Participants screened positive for alcohol-related problems if they endorsed at least one of the five items.

^{||} Smoking status was defined as never, former, or current based on questions of having used >100 cigarettes during their lifetime and the success of attempts to quit smoking.

[¶] Physical assault and sexual trauma were assessed using the questions, “Have you been hit, slapped, kicked, or otherwise physically hurt by someone?” and “Has anyone forced you to have an unwanted sexual act?”, respectively.

^{**} Scoring metrics were derived from the Medical Outcomes Study Short Form 36-Item Health Survey for Veterans.

Table 2. Adjusted* Hazard Ratios for Incident PTSD among Military Members
(N = 25,910).

Characteristics	Adjusted HR	95% CI	P Value
Stimulant prescription			
No	1.00		
Yes	3.66	2.48–5.41	<0.001
Deployment experience [†]			
Non-deployed	1.00		
Deployed with combat	1.61	1.41–1.83	<0.001
Deployed without combat	0.75	0.63–0.90	0.002
Sex			
Male	1.00		
Female	1.17	1.02–1.33	0.02
Birth cohort			
Pre-1960	1.00		
1960–1969	1.08	0.88–1.32	0.48
1970–1979	1.03	0.83–1.27	0.82
1980 and beyond	1.24	0.92–1.68	0.15
Race/ethnicity			
Non-Hispanic white	1.00		
Non-Hispanic black	1.35	1.15–1.58	<0.001
Other	1.44	1.24–1.66	<0.001
Highest level of education			
Some college or less	1.00		
Bachelor's or higher	0.82	0.63–1.05	0.11
Marital status			
Never married	1.00		
Married	0.93	0.82–1.07	0.32
Divorced, separated, or widowed	1.18	0.93–1.50	0.18
Occupation			
Combat specialist	1.00	0.87–1.15	0.97
Health care professional	0.79	0.65–0.97	0.02
Other	1.00		
Service branch			
Air Force	1.00		
Army	2.50	2.12–2.94	<0.001
Navy/Coast Guard	1.61	1.33–1.95	<0.001
Marine Corps	2.12	1.63–2.75	<0.001
Military pay grade			
Enlisted	1.00		
Officer	0.64	0.49–0.83	0.001
Alcohol-related problems [‡]			
No	1.00		

Yes	1.24	1.06–1.45	0.006
Cigarette smoking [§]			
Non-smoker	1.00		
Past smoker	1.25	1.09–1.43	0.001
Current smoker	1.50	1.31–1.72	<0.001
Prior physical assault/sexual trauma			
No	1.00		
Yes	1.98	1.75–2.23	<0.001
Mental component summary score [¶]			
<15th percentile	3.08	2.73–3.49	<0.001
15th–85th percentile	1.00		
>85th percentile	0.53	0.43–0.65	<0.001
Physical component summary score [¶]			
<15th percentile	2.22	1.96–2.51	<0.001
15th–85th percentile	1.00		
>85th percentile	0.82	0.69–0.97	0.02

CI, confidence interval; HR, hazard ratio; PTSD, post-traumatic stress disorder.

* Adjusted for all variables in the table.

† Deployment in support of the operations in Iraq and Afghanistan between baseline and the last completed follow-up.

‡ Assessed using five alcohol use questions from the Patient Health Questionnaire.

Participants screened positive for alcohol-related problems if they endorsed at least one of the five items.

§ Smoking status was defined as never, former, or current based on questions of having used >100 cigarettes during their lifetime and the success of attempts to quit smoking.

|| Physical assault and sexual trauma were assessed using the questions, “Have you been hit, slapped, kicked, or otherwise physically hurt by someone?” and “Has anyone forced you to have an unwanted sexual act?”, respectively.

¶ Scoring metrics were derived from the Medical Outcomes Study Short Form 36-Item Health Survey for Veterans.

Table 3. Adjusted Associations* for Stimulant Use, Cumulative Days' Supply, and Total Number of Stimulant Prescriptions with Incident PTSD (A) and among Military Members without a Diagnosis ADD/ADHD (B).

A.

	No PTSD n = 24,542 (%)	Incident PTSD n = 1368 (%)	Adjusted HR	95% CI	P Trend[†]
Stimulant prescription					
No	24,312 (99.1)	1341 (98.0)	1.00		
Yes	230 (0.9)	27 (2.0)	3.66	2.48–5.41	
Sum of days' supply of stimulants					<0.001
No prescription	24,312 (99.1)	1341 (98.0)	1.00		
30–89 days	110 (0.4)	7 (0.5)	2.83	1.45–5.48	
90+ days	120 (0.5)	20 (1.5)	4.29	2.64–6.96	
Number of stimulant prescriptions dispensed					<0.001
None	24,312 (99.1)	1341 (98.0)	1.00		
1–3 prescriptions	137 (0.5)	11 (0.8)	2.91	1.60–5.29	
4 or more prescriptions	93 (0.4)	16 (1.2)	4.46	2.67–7.46	

B.

	No PTSD n = 24,311 (%)	Incident PTSD n = 1347 (%)	Adjusted HR	95% CI	P Trend[†]
Stimulant prescription					
No	24,149 (99.3)	1330 (98.7)	1.00		
Yes	162 (0.7)	17 (1.3)	3.79	2.33–6.15	
Sum of days' supply of stimulants					<0.001
No prescription	24,149 (99.3)	1330 (98.7)	1.00		
30–89 days	100 (0.4)	6 (0.4)	2.50	1.19–5.25	
90+ days	62 (0.3)	11 (0.9)	5.94	3.15–11.18	
Number of stimulant prescriptions dispensed					<0.001
None	24,149 (99.3)	1330 (98.7)	1.00		
1–3 prescriptions	118 (0.6)	9 (1.0)	3.03	1.57–5.86	
4 or more prescriptions	44 (0.2)	8 (0.7)	5.26	2.60–10.67	

CI, confidence interval; HR, hazard ratio; PTSD, post-traumatic stress disorder.

* Adjusted for deployment experience, sex, birth year category, race/ethnicity, education, marital status, occupation, branch, pay grade, alcohol-related problems, smoking status, physical assault/sexual trauma, and mental and physical component summaries category.

[†] Wald's test with 1 df.

REPORT DOCUMENTATION PAGE

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB Control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD MM YY) 13 08 13		2. REPORT TYPE Report		3. DATES COVERED (from – to) 2001–2008	
4. TITLE Prescription Stimulants and the Development of Post-Traumatic Stress Disorder among U.S. Service Members				5a. Contract Number: 5b. Grant Number: 5c. Program Element Number: 5d. Project Number: 5e. Task Number: 5f. Work Unit Number: 60002	
6. AUTHORS Crum-Cianflone, Nancy F.; Melissa A Frasco, Cynthia LeardMann, Christopher Phillips; Jaime Horton, Dale W Russell, & Margaret Ryan					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Commanding Officer Naval Health Research Center 140 Sylvester Rd San Diego, CA 92106-3521					
Commanding Officer Naval Medical Research Center 503 Robert Grant Ave Silver Spring, MD 20910-7500					
Chief, Bureau of Medicine and Surgery 7700 Arlington Blvd Falls Church, VA 22042				8. PERFORMING ORGANIZATION REPORT NUMBER 13-47	
				10. SPONSOR/MONITOR'S ACRONYM(S) BUMED/NMRC	
				11. SPONSOR/MONITOR'S REPORT NUMBER(s)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.					
SUPPLEMENTARY NOTES					
13. Not to be publicly released prepublication.					
14. ABSTRACT Post-traumatic stress disorder (PTSD) occurs among both civilians and military personnel after traumatic events, and has become a signature wound of the recent conflicts in Iraq and Afghanistan. The relationship between novel risk factors, such as prescription stimulants, and the subsequent development of PTSD is unknown. We studied 25,971 military members from a large prospective cohort that began enrollment prior to September 11th, 2001. Medication prescriptions were obtained from the military Pharmacy Data Transaction System, and PTSD diagnosis was based on a validated survey instrument (PTSD Checklist–Civilian Version). The risk of incident PTSD with stimulant use was estimated using survival analyses, while adjusting for sociodemographic factors, military service characteristics, baseline mental and physical health status, deployment experiences (e.g., combat), and physical/sexual trauma. Overall, 1376 (5.3%) persons developed incident PTSD during follow-up. Prescription stimulants were significantly associated with incident PTSD (hazard ratio [HR], 3.34; 95% confidence interval [CI], 2.35–4.74; $p < 0.001$) in the adjusted model. The magnitude of this association exceeded that of a combat deployment and incident PTSD (HR, 1.62; 95% CI, 1.42–1.84; $p < 0.001$). A dose-related relationship between the days' supply and number of stimulant prescriptions with PTSD was noted. The findings suggest that prescription stimulants may increase the risk of subsequent development of PTSD. These data may inform the underlying pathogenesis of and preventive strategies for PTSD.					
15. SUBJECT TERMS stimulant prescription medication, post-traumatic stress disorder, PTSD, military, deployment, prospective study, incidence					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UNCL	18. NUMBER OF PAGES 28	18a. NAME OF RESPONSIBLE PERSON Commanding Officer
a. REPORT UNCL	b. ABSTRACT UNCL	c. THIS PAGE UNCL			18b. TELEPHONE NUMBER (INCLUDING AREA CODE) COMM/DSN: (619) 553-8429

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39-18